Syntekabio Inc.

The energy is high at BioTechX USA 2024! 💥 Our team is developing the solutions of tomorrow by connecting with industry leaders and sharing our breakthroughs in AI-driven drug discovery. From our keynote on overcoming data scarcity to deep dives into Flexible Molecular Docking, it’s been a fantastic opportunity to discuss how DeepMatcher® is accelerating R&D timelines. Don’t miss out on the chance to talk to us onsite - we’re still here and our partnering timeslots are filling up fast! Find out how AI can unlock your drug discovery potential by visiting us at Booth 401 or book a meeting here: https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio #bioTechXUSA #BioTechX

Read about the future of drug discovery and our AI-driven innovation in Genetic Engineering & Biotechnology News! 🌐 Find out about how Syntekabio is leveraging world-class AI and independent supercomputing to push the boundaries of pharmaceutical R&D. With DeepMatcher®, we can screen over 10 billion compounds to accelerate the discovery of first-in-class and best-in-class drug candidates. Learn how we’re empowering R&D teams to move from hit discovery to animal testing in as little as 12 months, and how our STB LaunchPad program helps reduce financial risk with our Develop Now, Pay Later offer! 👉 https://lnkd.in/ePyjSDPT Let’s innovate with confidence and bring new treatments to patients, faster. #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

💊 We’re setting new standards in drug discovery. Our DeepMatcher® AI platform utilizes advanced technologies like Flexible Molecular Docking (FMD) to analyze physical interactions between proteins and ligands. Our goal is to accelerate the discovery of first-in-class and best-in-class compounds and reduce the time, cost, and risks involved in drug discovery for Syntekabio’s clients, enabling them to bring important new treatments to patients. 🌍 Explore our latest insights on how we’re redefining the future of drug discovery: https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

Did you see the news? Syntekabio and Enamine Ltd. have announced a strategic collaboration to accelerate the discovery of optimized lead compounds and enhance drug development efficiency. By integrating Enamine’s extensive synthetic compound library with DeepMatcher®, this partnership is set to drive faster and more effective breakthroughs in drug discovery. #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio 

How has AI technology changed drug development processes? Find out what industry leaders across the life sciences, pharma, and biotech sectors had to say 🧬 – Contribute to our short survey to receive the results!📊 https://lnkd.in/eUbRs74v #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

Meet Syntekabio at BioTechX USA 2024 – September 17-18 in Philadelphia! Unlock the future of drug discovery with AI-driven innovation. Syntekabio is the Title Sponsor for BioTechX USA, and we invite you to join us for two insightful presentations and to visit our team. Here’s what you won’t want to miss: • 9:20 AM Tuesday, Sept. 17th - Keynote Presentation Leveraging Physics-Based AI Models to Overcome Data Scarcity in Drug Discovery Jonathan W., PhD, CTO, Syntekabio USA • 5:05 PM Tuesday, Sept. 17th - AI in Drug Discovery Presentation Flexible Molecular Docking for Neoantigen & Antibody Drug Prediction; Pre-Clinical Application Jongsun Jung, PhD, CEO, Syntekabio 💡 Discover how our advanced AI solutions can address your pipeline challenges. 📅 Stop by to connect with us and explore the latest in AI-driven drug discovery. Ask us about our Develop Now, Pay Later offer—Syntekabio invests in your success by helping you validate compounds with no upfront costs. Book a meeting with us to secure your spot and discuss your projects! https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

In the high-risk world of drug development, staying ahead requires more than just innovation—it demands transformative technology. 💡 STB LaunchPad from Syntekabio is designed to revolutionize your drug discovery process. With our powerful independent supercomputing enabling our proprietary AI platform, we streamline your pipeline to deliver results faster and more efficiently. 🔍 Why choose STB LaunchPad? •Accelerated Discovery: Benefit from rapid identification of promising drug candidates, reducing time to market. You will have access to over 10 billion compounds as well as 1,400 in vitro/in vivo compatible drug targets •Enhanced Precision: Utilize our DeepMatcher® AI platform for highly accurate drug discovery across diverse therapeutic areas. DeepMatcher® utilizes Flexible Molecular Docking (FMD) to continuously capture protein-ligand interactions/poses •Broad Coverage: We cover more than 70% of human diseases •Proven Results: Providing you with superior outcomes achieved through our proprietary discovery platform and a network of successful industry collaborations •Save costs: Compounds validated before you make significant R&D investment Discover how our cutting-edge technology can transform your research and development 👉 https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

Are you ready to accelerate your drug discovery with AI-driven solutions designed to minimize risk and maximize results? At Syntekabio we are investing in your success with our unique Develop Now, Pay Later offer - enabling fast hit and lead discovery, allowing you to focus on achieving breakthroughs. Start today with a complimentary feasibility study of your target proteins! 🧬 Benefit from: •In-depth evaluation: Leverage our advanced AI and supercomputing technology to assess the viability of your targets without any upfront costs. •Key insights: Gain valuable data on your compounds' potential, helping you make informed decisions before committing resources. •No financial commitment: You only pay once you obtain the agreed upon validated results 📋 Contact us today to schedule your complimentary Feasibility Study and accelerate your drug discovery process: https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

📰 Unlock the Future of Drug Discovery with Syntekabio’s Exclusive Newsletter! 📰 Step into the future with Syntekabio, where AI meets drug discovery in ways never before imagined. Our innovative approaches are not just keeping up with the industry—they’re setting new standards. Subscribe today to keep your finger on the pulse of cutting-edge developments that could change the way you approach R&D. 🌟 Why Subscribe? ➡ Exclusive Insights: Gain insider access to our cutting-edge programs, including our game-changing offer where we invest in your success, with Develop Now, Pay Later. ➡ In-Depth Articles: Dive into comprehensive articles that explore the latest breakthroughs and trends in AI and drug discovery. ➡ Early Access to New Opportunities: Stay ahead with the first look at new offerings, including our complimentary feasibility testing and customized AI solutions to accelerate your R&D. 📩 Don’t miss this chance to enhance your expertise and stay at the forefront of innovation. Subscribe to our newsletter today and be part of the future of drug discovery. https://lnkd.in/eXC4EuiF #AI #DrugDiscovery #healthcareinnovation #Pharma #machinelearning #oncology

We’re thrilled to announce the launch of our groundbreaking Develop Now, Pay Later offer, where we invest in your success! This game-changing opportunity enables pharmaceutical innovators to leverage the power of our AI-driven STB LaunchPad program—without any upfront costs! Here’s what sets it apart: 🔹 Compounds can be validated before you make significant R&D investment 🔹 Highly flexible, physics-based, disease-agnostic AI platform that can identify novel small molecules, antibodies and cancer neoantigens 🔹 Utilizes Flexible Molecular Docking (FMD) to continuously capture protein-ligand interactions/poses. 🔹 Demonstrated outperformance of industry benchmarks 🔹 Coverage of over 70% of human diseases 🔹 Access to over 10 billion compounds as well as 1,400 in vitro/in vivo compatible drug targets 💡 Imagine having the flexibility to initiate high-impact projects without the financial strain. Now you can do just that—innovate boldly with minimized risk. Pay only when you see the agreed validated results. 🔗 Ready to explore this unique opportunity? Learn more about how we can accelerate your R&D strategy: https://lnkd.in/eXC4EuiF #machinelearning #AI #DrugDiscovery #healthcareinnovation #oncology